In short
Clinical trials are investigating Rondaptivon Pegol in people with type 2B von Willebrand disease. These studies are looking at safety, efficacy, and effects on bleeding-related measures such as platelet counts. The target group is patients with this rare bleeding disorder.
Key points
- Clinical trials are studying Rondaptivon Pegol in people with type 2B von Willebrand disease, a rare bleeding disorder. The available trial is a Phase 2 interventional study with 6 participants. Researchers are looking at safety and efficacy, with co-primary endpoints that include platelet counts and the number of monthly bleeding events. The brief trial summary also says the study examines VWF indices, FVIII, and bleeding. The study is authorised and uses a subcutaneous comparison against 0.9% sodium chloride solution.
Trial overview
The available clinical trial for Rondaptivon Pegol is titled “Efficacy and Safety of BT200 (rondaptivon pegol) in Patients with Type 2B von Willebrand disease.” The trial is an interventional study, which means researchers give a study treatment and then measure the results.
This study is in Phase 2 and has been authorised. The trial is focused on people with type 2B von Willebrand disease.
Who is being studied
The target condition is Von Willebrand's Disease Type 2B. This is the only condition listed in the trial data, so the study is aimed at patients with this rare bleeding disorder.
The enrollment is 6 people, which means the study is very small. The trial data do not give more detailed participation rules, such as age limits or other entry requirements.
What the study measures
The brief summary says the study is looking at the effects of BT200, which is named as rondaptivon pegol, on platelet count, VWF indices, FVIII, and bleeding in type 2B VWD. In simple terms, the researchers want to see how the treatment affects blood clotting-related measures and bleeding.
The primary outcomes are listed as platelet counts and the number of monthly bleeding events. A primary outcome is the main result a trial is designed to measure.
Trial design and treatment groups
The interventions listed are 0.9% sodium chloride solution and Rondaptivon Pegol. Both are given by subcutaneous use, which means under the skin.
The trial data show a dose of 12 mg/kg for Rondaptivon Pegol and 0.8 ml for the sodium chloride solution. The data do not explain the full study schedule or how the comparison is organized beyond these listed interventions.
Study status and size
The study status is Authorised, which means it has permission to proceed according to the source data. The planned enrollment is 6 participants, so this is a small early-stage study.
Because the trial is small, its main purpose is likely to gather early information about whether the treatment should be studied further in this condition. The source data do not report final results.
What this means for patients
For patients, this trial means researchers are testing whether Rondaptivon Pegol may help in type 2B von Willebrand disease by improving clotting-related measures and reducing bleeding. The study is focused on a rare condition and uses clear outcome measures such as platelet count and monthly bleeding events.
The trial data do not provide broader conclusions yet, because only the study plan and design details are available.